Rhythm Reports Q2 2026 Sales of $71.3M, Launching IMCIVREE for HO
Rhythm Pharmaceuticals reports second-quarter net product revenue of $71.3 million, up 19% sequentially, following the successful U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company attributed the performance to increased demand for the treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day